Global Gene Expression Profiling Reveals SPINK1 as a Potential Hepatocellular Carcinoma Marker

Background Liver cirrhosis is the most important risk factor for hepatocellular carcinoma (HCC) but the role of liver disease aetiology in cancer development remains under-explored. We investigated global gene expression profiles from HCC arising in different liver diseases to test whether HCC development is driven by expression of common or different genes, which could provide new diagnostic markers or therapeutic targets. Methodology and Principal Findings Global gene expression profiling was performed for 4 normal (control) livers as well as 8 background liver and 7 HCC from 3 patients with hereditary haemochromatosis (HH) undergoing surgery. In order to investigate different disease phenotypes causing HCC, the data were compared with public microarray repositories for gene expression in normal liver, hepatitis C virus (HCV) cirrhosis, HCV-related HCC (HCV-HCC), hepatitis B virus (HBV) cirrhosis and HBV-related HCC (HBV-HCC). Principal component analysis and differential gene expression analysis were carried out using R Bioconductor. Liver disease-specific and shared gene lists were created and genes identified as highly expressed in hereditary haemochromatosis HCC (HH-HCC) were validated using quantitative RT-PCR. Selected genes were investigated further using immunohistochemistry in 86 HCC arising in liver disorders with varied aetiology. Using a 2-fold cut-off, 9 genes were highly expressed in all HCC, 11 in HH-HCC, 270 in HBV-HCC and 9 in HCV-HCC. Six genes identified by microarray as highly expressed in HH-HCC were confirmed by RT qPCR. Serine peptidase inhibitor, Kazal type 1 (SPINK1) mRNA was very highly expressed in HH-HCC (median fold change 2291, p = 0.0072) and was detected by immunohistochemistry in 91% of HH-HCC, 0% of HH-related cirrhotic or dysplastic nodules and 79% of mixed-aetiology HCC. Conclusion HCC, arising from diverse backgrounds, uniformly over-express a small set of genes. SPINK1, a secretory trypsin inhibitor, demonstrated potential as a diagnostic HCC marker and should be evaluated in future studies.

[1]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[2]  J. Olsen,et al.  Cancer risk following primary hemochromatosis: A population‐based cohort study in Denmark , 1995, International journal of cancer.

[3]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[4]  R. Gish,et al.  Development of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients: A Case Series , 2011, Digestive Diseases and Sciences.

[5]  Dennis B. Troup,et al.  NCBI GEO: archive for functional genomics data sets—10 years on , 2010, Nucleic Acids Res..

[6]  H. Hsu,et al.  Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. , 2007, European journal of cancer.

[7]  K. Matsubara,et al.  Identification of the IL-6-responsive element in an acute-phase-responsive human pancreatic secretory trypsin inhibitor-encoding gene. , 1993, Gene.

[8]  O. Kozawa,et al.  Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican‐3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  Thomas D. Wu,et al.  The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. , 2012, Genome research.

[10]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[11]  R. Thimme,et al.  Immunobiology of hepatocellular carcinoma , 2012, Langenbeck's Archives of Surgery.

[12]  Trypsinogen-1, -2 and tumour-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas. , 2001, Scandinavian journal of clinical and laboratory investigation.

[13]  L. Roberts,et al.  The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. , 2011, Seminars in cancer biology.

[14]  M. Yuen,et al.  Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. , 2009, Journal of hepatology.

[15]  I. Tannock,et al.  Phase II study of cytarabine in men with docetaxel‐refractory, castration‐resistant prostate cancer with evaluation of TMPRSS2‐ERG and SPINK1 as serum biomarkers , 2012, BJU international.

[16]  A. Floreani,et al.  Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: Comparative analysis from two centers , 2009, Hepatology.

[17]  L. A. Kazal,et al.  Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. , 1948, Journal of the American Chemical Society.

[18]  U. Stenman,et al.  Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. , 1982, The Journal of biological chemistry.

[19]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[20]  U. Stenman.  SPINK1: a new therapeutic target in cancer? , 2011, Clinical chemistry.

[21]  J. Kim,et al.  Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. , 2011, Hepato-gastroenterology.

[22]  M. Miyazaki,et al.  Relationship Between Pancreatic Secretory Trypsin Inhibitor and Early Recurrence of Intrahepatic Cholangiocarcinoma Following Surgical Resection , 2006, The American Journal of Gastroenterology.

[23]  T. Block,et al.  Hepatitis B and Hepatitis C Virus Replication Upregulates Serine Protease Inhibitor Kazal, Resulting in Cellular Resistance to Serine Protease-Dependent Apoptosis , 2009, Journal of Virology.

[24]  D. Sayed,et al.  Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. , 2011, Annals of hepatology.

[25]  O. Itkonen,et al.  Validation and comparison of tumor-associated trypsin inhibitor (TATI) immunoassays. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[26]  C. Hellerbrand,et al.  Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications , 2010, Gut.

[27]  S. Köklü,et al.  Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma , 2011, Journal of clinical laboratory analysis.

[28]  M. Rubin,et al.  INTEGRATION OF ERG GENE MAPPING AND GENE‐EXPRESSION PROFILING IDENTIFIES DISTINCT CATEGORIES OF HUMAN PROSTATE CANCER , 2009, BJU international.

[29]  N. Elwan,et al.  Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. , 2010, Archives of medical research.

[30]  P. Galle,et al.  Hepatocellular carcinoma in patients with autoimmune hepatitis. , 2009, World journal of gastroenterology.

[31]  J. Furuse.  Growth factors as therapeutic targets in HCC. , 2008, Critical reviews in oncology/hematology.

[32]  A. Paju,et al.  Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma. , 2001, The Journal of urology.

[33]  M. Kew.  Hepatitis B virus x protein in the pathogenesis of hepatitis B virus‐induced hepatocellular carcinoma , 2011, Journal of gastroenterology and hepatology.

[34]  M. Mattioli,et al.  Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non–iron‐related chronic liver disease , 2001, Hepatology.

[35]  M. Salto‐Tellez,et al.  Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer , 2011, EMBO molecular medicine.

[36]  U. Stenman,et al.  Immunochemical demonstration of an ovarian cancer‐associated urinary peptide , 1982, International journal of cancer.

[37]  S. Cho,et al.  Elevated Plasma Osteopontin Levels in Patients with Hepatocellular Carcinoma , 2006, The American Journal of Gastroenterology.

[38]  R. Hultcrantz,et al.  Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. , 2003, Gastroenterology.

[39]  M. Monden,et al.  Specific expression of the pancreatic‐secretory‐trypsin‐inhibitor (PSTI) gene in hepatocellular carcinoma , 1993, International journal of cancer.

[40]  Chien-Jen Chen,et al.  Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  U. Stenman,et al.  Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. , 2003, Urology.

[42]  K. Jirström,et al.  Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients , 2010, BMC Cancer.

[43]  S. Altekruse,et al.  Hepatocellular Carcinoma Confirmation, Treatment, and Survival in Surveillance, Epidemiology, and End Results Registries, 1992‐2008 , 2012, Hepatology.

[44]  U. Stenman,et al.  Tumor‐associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal‐cell carcinoma patients , 1999, International journal of cancer.

[45]  U. Stenman.  Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development. , 2011, Asian journal of andrology.

[46]  Michiie Sakamoto,et al.  Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.

[47]  G. Androulakis,et al.  Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies. , 2004, Clinical Biochemistry.

[48]  S. Varambally,et al.  Therapeutic Targeting of SPINK1-Positive Prostate Cancer , 2011, Science Translational Medicine.

[49]  M. Kenichi,et al.  Identification of the IL-6-responsive element in an acute-phase-responsive human pancreatic secretory trypsin inhibitor-encoding gene , 1993 .

[50]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[51]  U. Stenman,et al.  Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. , 2007, European urology.

[52]  John T. Wei,et al.  The role of SPINK1 in ETS rearrangement-negative prostate cancers. , 2008, Cancer cell.

[53]  Tapio Visakorpi,et al.  Association of SPINK1 Expression and TMPRSS2:ERG Fusion with Prognosis in Endocrine-Treated Prostate Cancer , 2010, Clinical Cancer Research.

[54]  William M. Lee,et al.  Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. , 2009, Gastroenterology.

[55]  Arthur Liberzon,et al.  Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. , 2011, Gastroenterology.

[56]  M. Levrero.  Viral hepatitis and liver cancer: the case of hepatitis C , 2006, Oncogene.

[57]  Ibrahim Emam,et al.  ArrayExpress update—an archive of microarray and high-throughput sequencing-based functional genomics experiments , 2010, Nucleic Acids Res..

[58]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[59]  H. El‐Serag,et al.  Risk factors for the rising rates of primary liver cancer in the United States. , 2000, Archives of internal medicine.

[60]  A. Castells,et al.  Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus–related cirrhosis , 2001, American Journal of Gastroenterology.

[61]  G. Mieli-Vergani,et al.  Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow‐up and screening , 2008, Hepatology.

[62]  D. Harnois.  Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease , 2009 .

[63]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[64]  K. Partanen,et al.  Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. , 1995, Anticancer research.

[65]  L. Nicholson,et al.  Chronic inflammation and hepatocellular carcinoma. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[66]  J. Davis.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[67]  I. Markaki,et al.  Co-expression of trypsin and tumour-associated trypsin inhibitor (TATI) in colorectal adenocarcinomas. , 2003, Histology and histopathology.

[68]  S. Nordling,et al.  High tissue expression of tumour‐associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer , 2005, Histopathology.

[69]  U. Stenman,et al.  Biochemistry and Clinical Role of Trypsinogens and Pancreatic Secretory Trypsin Inhibitor , 2006, Critical reviews in clinical laboratory sciences.